Impact of GST Polymorphisms on Long-Term Toxicities in Testicular Cancer Survivors
Author Information
Author(s): Jan Oldenburg, Sigrid M. Kraggerud, Marianne Brydøy, Milada Cvancarova, Ragnhild A. Lothe, Sophie D. Fossa
Primary Institution: The Norwegian Radiumhospital, Oslo, Norway
Hypothesis
The study investigates the association between polymorphisms in GST genes and self-reported long-term toxicities in testicular cancer survivors.
Conclusion
Long-term self-reported chemotherapy-induced toxicities in testicular cancer survivors are associated with functional polymorphisms in GSTP1 and GSTM1.
Supporting Evidence
- All six evaluated toxicities were significantly associated with the cumulative dose of cisplatin and/or bleomycin.
- TCSs with GSTP1-GG were significantly less bothered by paresthesias and tinnitus compared to those with GSTP1-AG or GSTP1-AA.
- Absence of functional GSTM1 protected against hearing impairment.
Takeaway
This study found that certain genetic variations can affect how testicular cancer survivors experience long-term side effects from chemotherapy.
Methodology
The study analyzed DNA from 238 testicular cancer survivors who completed a survey on long-term toxicities, focusing on GST polymorphisms and their association with reported symptoms.
Potential Biases
Potential bias due to reliance on self-reported data and lack of pre-treatment evaluations.
Limitations
The study relied on self-reported symptoms, which may not accurately reflect objective measures of toxicity.
Participant Demographics
Median age at diagnosis was 29 years, with a range of 15 to 64 years; the majority were non-seminoma patients.
Statistical Information
P-Value
p = 0.008 for tinnitus, p = 0.025 for hearing impairment
Confidence Interval
[0.22–0.96] for paresthesias, [1.08–3.03] for hearing impairment
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website